Related references
Note: Only part of the references are listed.Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Jay S. Charleston et al.
NEUROLOGY (2018)
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Dystrophin quantification Biological and translational research implications
Karen Anthony et al.
NEUROLOGY (2014)
Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice
Maaike van Putten et al.
FASEB JOURNAL (2013)
Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials
Virginia Arechavala-Gomeza et al.
NEUROMUSCULAR DISORDERS (2010)
Share Paper
